Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
182.35 USD   +0.48%
12/02Insider Sell: Moderna
MT
12/02Insider Sell: Moderna
MT
12/02Cornell University : Experimental vaccines offer long-term protection against severe COVID
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Over 4 million Americans administered updated COVID boosters, says CDC

09/23/2022 | 08:47am EST
FILE PHOTO: People receive their second COVID-19 boosters in Waterford, Michigan

(Reuters) - The U.S. Centers for Disease Control and Prevention reported on Thursday that 4.4 million people had received updated COVID-19 booster shots, a few weeks into the government's new vaccination campaign.

The United States began its rollout of the Omicron-tailored shots from Pfizer/BioNTech and Moderna earlier this month.

A federal health agency said on Tuesday that over 25 million doses of the so-called bivalent shots had been sent out. That consisted of mostly the Pfizer/BioNTech vaccine, as production of the Moderna vaccine ramps up.

The redesigned boosters aim to tackle the BA.5 and BA.4 Omicron subvariants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the United States, based on latest data.

(Reporting by Manas Mishra in Bengaluru; editing by Uttaresh.V)


ę Reuters 2022
All news about MODERNA, INC.
12/02Insider Sell: Moderna
MT
12/02Insider Sell: Moderna
MT
12/02Cornell University : Experimental vaccines offer long-term protection against severe COVID
AQ
12/01Transcript : Moderna, Inc. Presents at Piper Sandler 34th Annual Healthcare C..
CI
11/30Moderna exec says COVID trials improved diversity recruiting
RE
11/30Insider Sell: Moderna
MT
11/30Insider Sell: Moderna
MT
11/30Britain is little better prepared for future pandemics - Former UK vaccine chief
RE
11/28Insider Sell: Moderna
MT
11/28Insider Sell: Moderna
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 089 M - -
Net income 2022 8 897 M - -
Net cash 2022 12 022 M - -
P/E ratio 2022 8,45x
Yield 2022 -
Capitalization 70 055 M 70 055 M -
EV / Sales 2022 3,04x
EV / Sales 2023 6,42x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 182,35 $
Average target price 211,25 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727
CELLTRION, INC.-12.12%18 382